Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

This publication has 44 references indexed in Scilit:

• The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer
  European Journal of Surgical Oncology, 2005
• Serum HCGβ and CA 72-4 Are Stronger Prognostic Factors than CEA, CA 19-9 and CA 242 in Pancreatic Cancer
  Oncology, 2004
• Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
  European Journal of Surgical Oncology, 2000
• Effectiveness of Multivariate Analysis of Tumor Markers in Diagnosis of Pancreatic Carcinoma
  Pancreas, 1994
• Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
  Gut, 1994
• CA 494—a new tumor marker for the diagnosis of pancreatic cancer
  International Journal of Cancer, 1993
• Serum Levels of CA 19-9 and CA 50 in Relation to Lewis Blood Cell Status in Patients with Malignant and Benign Pancreatic Disease
  Pancreas, 1993
• Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography
  New England Journal of Medicine, 1992
• Comparative Study of CA-50 (Time-Resolved Fluoroimmunoassay), Span-1, and CA19-9 in the Diagnosis of Pancreatic Cancer
  Scandinavian Journal of Gastroenterology, 1991
• Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer.
  Gut, 1985